IBD: Ulcerative Colitis
IBD: Switching from a Biologic to a Biosimilar
Updated March 20201
Having to change any kind of medication can be very stressful. While CDHF believes in patient-physician choice, we acknowledge political policy decisions and our organization is committed to providing clear and unbiased information and resources for patients. Both biologics and biosimilars have gone through rigorous standards for authorization by Health Canada, to which both have been found safe and effective for use in Inflammatory Bowel Disease (IBD). Watch this video to learn more about switching from a biologic to a biosimilar.
Related Articles
Hot off the Presses: The Latest IBD Information from Scientific Meetings with Dr. Silverberg Webinar
In this educational webinar, Dr. Silverberg reviewed the most recent scientific findings in Inflammatory Bowel Disease (IBD) and discussed the role of diet and gut bacteria […]
Helping inflammatory bowel disease (IBD) patients best understand transitioning/switching from a reference biologic to a biosimilar.
Date Written: 09-2020 *This information is intended for educational purposes and is not intended to replace recommendations that have been provided by your Physician and Health […]